The FDA has approved application ANDA085964 for an oral tablet product named Acetaminophen and Codeine Phosphate.
The tablet contains 300 mg of acetaminophen and 60 mg of codeine phosphate per dose. It is marketed by Sandoz and is currently listed with a marketing status of discontinued.
Submission history includes an original submission (number 1) approved on 1978‑07‑18, followed by several supplemental labeling submissions (numbers 40, 42, 43, 44, 45) approved between 1988 and 1991.
The product is not designated as a reference drug and does not have a reference standard.
Actualizaciones regulatorias5 sept 2026•1 min de lectura
FDA Approves ANDA085964 for Acetaminophen and Codeine Phosphate Tablet
The FDA approved ANDA085964 for Sandoz's oral tablet containing 300 mg acetaminophen and 60 mg codeine phosphate; the product is listed as discontinued after multiple labeling submissions.
Recopilado por el equipo de PharmaCountry · Fuente: FDA.gov
Calificaciones
(0)
(0)
(0)
(0)
(0)
Más artículos
Ver todos los artículosInvestigación e Informes
Global Finished Dosage Manufacturing Landscape 2026
5 oct 2026
Actualizaciones regulatoriasKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28 sept 2026
AnálisisPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28 sept 2026
Deja tu valoración